Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taneasy vs Fluimucil in COPD
NCT06828120Phase 4Completed
- Sponsor
- Bun Yao Biotechnology Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Sep 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial of azelastine + fluticasone in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Bun Yao Biotechnology Co., Ltd. Primary endpoint: Safety and Efficacy of Taneasy 600mg granules and Fluimucil 600mg granules at 1 month. Started Feb 2025; status: completed.
02
Drugs
azelastine + fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06828120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06828120.